Portfolio

MitraVerse

Is developing a novel two component mitral valve replacement solution designed from day one to be delivered transseptal and not obstruct the left ventricle outflow tract.

Unique features our device has over the competition:

1) Maintain native leaflet function until second component (valve) is deployed into the Docking Station 2) Our design minimizes LVOT and thrombus allowing us to expand the patient population of use 3) The two component system is smaller than 22Fr and since our two components do not require clocking or complicated delivery methods it is easier to deploy

Development Status

We are in the process of completing our design dossier allowing us to move rapidly toward developing and de-risking the design oncer our first round of financing is complete

Intellectual Property

Patent applications filed

Funding Status

We are in the process of seeking investors to finance our development efforts through FDA submission and our First-in-Human clinical study.

Financing and Timeline:

$12 million / 48 months to complete FDA submission and First-in-Human study

For investment inquires please contact

MITRAVERSE

Is developing a commercial ready, innovative, patented solution to dramatically improve the procedural ease, clinical efficiency and overall success of treating Barrett’s Esophagus; effectively reducing the risk of esophageal cancer in millions of patients worldwide.

Unique features our device has over the competition:

1) Vapor is used to ablate the tissue 2) Single treatment is needed due to how the body absorbs vapor vs being burned requiring multiple treatments 3) vapor is easy and safe to control

Development Status

Our feasibility pre-clinical work on the bench and in animals

Intellectual Property

Patent issued

Funding Status

We are in the process of seeking investors to finance our development efforts through FDA approval and our First-in-Human clinical study.

Financing and Timeline:

$8 million / 24 months to complete FDA approval and First-in-Human study

For investment inquires please contact

NEBULA MEDICAL

Is developing a commercial ready, innovative, patented solution to dramatically improve ease, efficiency and success of current vascular procedures thereby improving results and diminish disability and death in millions of patients around the world. Our primary focus is improving the safety, efficiency, and time requirement of crossing procedures related to Chronic Total Occlusions in both CAD and PAD.

Unique features our device has over the competition:

1) Vapor is used to ablate the tissue 2) Single treatment is needed due to how the body absorbs vapor vs being burned requiring multiple treatments 3) vapor is easy and safe to control

Development Status

Our feasibility pre-clinical work on the bench and in animals

Intellectual Property

Patent issued

Funding Status

We are in the process of seeking investors to finance our development efforts through FDA approval and our First-in-Human clinical study.

Financing and Timeline:

$4 million / 24 months to complete FDA approval and First-in-Human study

For investment inquires please contact

OCCLUZION VASCULAR

Tempus Medical

Is in the process of developing an intuitively designed temporary pacing catheter that addresses multiple unmet needs while improving patient outcomes and save cost.

Unique features are catheter has vs the competition:

1) Designed to be delivery without fluoroscopy guidance 2) Multiple electrodes allow device to be operated in unipolar and bipolar modes 3) Designed to not lose capture due to dislodgment

Development Status

We are in the process of completing our pre-clinical work in animals to down select our design allowing us to move into concept freeze

Intellectual Property

Patent application filed, in the process of expanding IP

Funding Status

We are in the process of seeking investors to finance our development efforts through FDA approval and our First-in-Human clinical study.

Financing and Timeline:

$6 million / 24 months to complete FDA approval and First-in-Human study

For investment inquires please contact

TEMPUS MEDICAL